US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

China Score, Inc.

0.0000

0.0000

Volume:- -

Turnover:- -

Market Cap:101.00

PE:- -

High:0.0000

Open:0.0000

Low:0.0000

Close:0.0000

52wk High:0.0000

52wk Low:0.0000

Shares:101.00M

Float Shares:- -

Volume Ratio:2.23

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Press Release: atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CIAS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CIAS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CIAS\",,,,,undefined,":{"symbol":"CIAS","market":"US","secType":"STK","nameCN":"China Score, Inc.","latestPrice":0.000001,"timestamp":1770411600000,"preClose":0.000001,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":0,"shares":101000000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:00:00 EST Delay","open":0.000001,"high":0.000001,"low":0.000001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.000001,"volumeRatio":2.2347367779753746},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CIAS\",,,,,undefined,":{"symbol":"CIAS","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.2347367779753746,"shares":101000000,"dividePrice":0,"high":0.000001,"amplitude":0,"preClose":0.000001,"low":0.000001,"week52Low":0.000001,"pbRate":"--","week52High":0.000001,"institutionHeld":0,"latestPrice":0.000001,"eps":0,"divideRate":0,"volume":0,"delay":15,"open":0.000001,"prevYearClose":0.000001,"prevWeekClose":0,"prevMonthClose":0,"prevQuarterClose":0,"fiveDayClose":0,"twentyDayClose":0,"sixtyDayClose":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CIAS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-11","symbol":"CIAS","reason":null,"defaultRemindTime":1731335400000,"announcedDate":"2024-11-08","type":"delisting","dateTimestamp":1731301200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CIAS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CIAS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CIAS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559954804","title":"atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2559954804","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559954804?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:00","pubTimestamp":1755169200,"startTime":"0","endTime":"0","summary":"Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported posi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133317/0/en/atai-Life-Sciences-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI","CIAS","BK4007","BK4539"],"gpt_icon":0},{"id":"2554979477","title":"Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2554979477","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554979477?lang=en_us&edition=fundamental","pubTime":"2025-07-26 04:05","pubTimestamp":1753473900,"startTime":"0","endTime":"0","summary":"Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significanc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/25/3121996/0/en/Recognify-Life-Sciences-Provides-Update-on-Phase-2b-Trial-of-Inidascamine-in-Patients-with-Cognitive-Impairment-Associated-with-Schizophrenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CIAS"],"gpt_icon":0},{"id":"2535491042","title":"Press Release: atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2535491042","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535491042?lang=en_us&edition=fundamental","pubTime":"2025-05-14 19:00","pubTimestamp":1747220400,"startTime":"0","endTime":"0","summary":"With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments. -- Anticipate topline data midyear from the Phase 2b clinical trial of. BPL-003 in patients with treatment-resistant depression  - the. largest controlled trial of mebufotenin and the first and only such trial. -- Dosed the first patient in the exploratory Phase 2 study of EMP-01 (oral. R-MDMA) for the treatment of social anxiety; topline data anticipated in. -- Continued enrollment in Elumina, a Phase 2 study of VLS-01 (buccal film. DMT) in patients with TRD; topline data are anticipated in Q1'26. Cash, cash equivalents, short-term securities, and public equity holdings expected to fund operations into 2027. -- VLS-01 is an investigational proprietary oral transmucosal film. formulation of DMT applied to the buccal surface, design","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CIAS","BK4007","ATAI","BK4539"],"gpt_icon":0},{"id":"2520409455","title":"atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2520409455","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520409455?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:00","pubTimestamp":1742212800,"startTime":"0","endTime":"0","summary":"- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical tr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/17/3043651/0/en/atai-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CIAS","BK4539","ATAI","BK4007"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CIAS\",params:#limit:6,delay:false,,,undefined,":[]}}